BML Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$12.5M |
| 2 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$9.16M |
| 3 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
+$5.11M |
| 4 |
EMBK
Embark Technology, Inc. Common Stock
EMBK
|
+$4.73M |
| 5 |
Oramed Pharmaceuticals
ORMP
|
+$4.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$11M |
| 2 |
Abercrombie & Fitch
ANF
|
+$7.66M |
| 3 |
Disc Medicine
IRON
|
+$6.5M |
| 4 |
Verrica Pharmaceuticals
VRCA
|
+$5.81M |
| 5 |
Richardson Electronics
RELL
|
+$2.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.31% |
| 2 | Consumer Discretionary | 14.79% |
| 3 | Technology | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lisata Therapeutics
LSTA
$9.93M
| $791K | 0.68% |
243,839
| – | – |
|
27
NextCure
NXTC
$20.4M
| $454K | 0.39% |
+25,539
| New | +$492K |
|
|
LENZ
28
LENZ Therapeutics
LENZ
$179M
| $373K | 0.32% |
+21,756
| New | +$352K |
|
29
Passage Bio
PASG
$14.5M
| $323K | 0.28% |
16,873
| – | – |
|
30
Adicet Bio
ACET
$77.6M
| $173K | 0.15% |
1,875
| – | – |
|
31
Neurogene
NGNE
$672M
| $16.6K | 0.01% |
+1,187
| New | +$13.9K |
|
32
CalciMedica
CALC
$11.7M
| – | – |
-88,282
| Closed | -$618K |
|
|
ELEV
33
DELISTED
Elevation Oncology
ELEV
| – | – |
-39,963
| Closed | -$38K |
|
|
34
Richardson Electronics
RELL
$244M
| – | – |
-95,359
| Closed | -$2.03M |
|
|
SPRB
35
Spruce Biosciences
SPRB
$114M
| – | – |
-2,958
| Closed | -$243K |
|
Similar funds
BML Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, BML Capital Management held 35 positions worth $116M, up 11% from $105M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
BML Capital Management deployed $10.3M of net new capital in Q1 2023, opening 10 new positions and adding to 4 existing holdings. Its largest new stake was iShares 0-3 Month Treasury Bond ETF: 125,000 shares worth $12.6M.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 65% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Enliven Therapeutics, an estimated $11M trimmed.
- BML Capital Management's largest Q1 2023 buy was iShares 0-3 Month Treasury Bond ETF: 125,000 shares worth $12.6M.
- BML Capital Management added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q1 2023, an estimated $9.16M increase.
- BML Capital Management's biggest Q1 2023 reduction was Enliven Therapeutics, cutting an estimated $11M.
- BML Capital Management fully exited Richardson Electronics in Q1 2023, selling an estimated $2.03M.
- BML Capital Management's ten largest holdings make up 68% of its $116M portfolio in Q1 2023.
- BML Capital Management opened 10 new positions and closed 4 in Q1 2023.
- BML Capital Management's portfolio value rose 11% quarter-over-quarter to $116M.
Based on BML Capital Management's 13F filing for Q1 2023, filed 14 Apr 2023.